AML is characterized by a great variability in genetic profile, sensitivity to chemotherapy and prognosis. Allogeneic hematopoietic stem cell transplantation (HSCT) represents the best curative option for high-risk patients, but relapses frequently occur, and can be observed even after several months of apparent morphological remission. New therapeutic options are becoming available, but results are unsatisfactory when they are enacted in overt hematological recurrence. In this context, the early detection of an expanding leukemic clone can predict a future clinical relapse, and prompt preemptive therapies. Unfortunately, unlike other hematologic malignancies, AML lacks universal disease-specific genetic markers that can be tracked for identification of minimal residual disease, and early relapse recognition has often to rely on leukemia-associated immunophenotype, on the selective overexpression of transcripts in leukemic blasts, or on hematopoietic chimerism as a surrogate marker of reappearance of pathological hematopoiesis. Still, the constant progress in our knowledge of the genetic landscape of AML is offering new valuable markers for MRD monitoring.
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Unfortunately, unlike other hematologic malignancies, AML lacks universal disease-specific genetic markers that can be tracked for identification of minimal residual disease, and early relapse recognition has often to rely on leukemia-associated immunophenotype, on the selective overexpression of transcripts in leukemic blasts, or on hematopoietic chimerism as a surrogate marker of reappearance of pathological hematopoiesis. Still, the constant progress in our knowledge of the genetic landscape of AML is offering new valuable markers for MRD monitoring. 2 Mutations in the nucleophosmin 1 (NPM1 mut ) gene are among the most frequent genetic alterations in AMLs, occurring in approximately one-third of the cases, and are associated with specific morphological, phenotypic and clinical features. 3 More than 40 mutations have been described, but 75% of cases show the same genetic alteration in exon 12, named NPM1 mutation A. NPM1 mut represent relatively early events in leukemogenesis, and thus can be considered stable markers to be tracked throughout leukemia history and clonal evolution. 4, 5 In line with that, numerous studies have demonstrated the usefulness of landmark analyses and longitudinal monitoring of NPM1 mut in AML patients after chemotherapy. 6, 7 However, information on the clinical utility of NPM1 mut quantitative monitoring in the post-transplantation setting are to date more limited, [7] [8] [9] and thus represent the specific focus of our present study.
Between January 2011 and June 2014, our center performed 135 consecutive allogeneic HSCTs for patients suffering from AML; among them 28 (21%) carried NPM1 mutations at diagnosis (mutation A in 27 cases, mutation B in one case). Patient and transplant characteristics are summarized in Table 1 . To monitor the persistence and burden of NPM1 mutations we employed real time quantitative PCR (RT-qPCR), using as a reference the ABL gene and as a template the cDNA, synthesized upon retrotranscription of total RNA extracted from bone marrow (BM) samples collected at serial time points after allogeneic HSCT. All the results presented in this study were analyzed retrospectively, and no clinical decision was directly prompted by an increase in NPM1 mut levels. Results from NPM1 mut monitoring were compared with those obtained from qPCR quantification of Wilms Tumor 1 (WT1) transcript and host-specific hematopoietic chimerism, both more commonly determined in the peripheral blood, but here measured in the same BM samples used for NPM1 mut analysis.
Details on all the methods employed in the study are provided as Supplementary Information. All the 28 patients with NPM1 mut AML achieved hematological remission at the BM evaluation performed 1 month after the transplant. Eleven of these patients (39%) experienced posttransplantation relapse: six had received HCST in morphological remission, three of them with positive NPM1 mut transcript in the pre-transplant BM evaluation. Out of the eleven patients who experienced relapse, ten remained positive for NPM1 mutation at the time of relapse, whereas one, which was NPM1 mut at diagnosis, was persistently negative for NPM1 mut during all his follow-up and ultimately experienced a NPM1 wild-type relapse. Interestingly, at the time of diagnosis leukemic cells from this patient displayed a mutation in DNMT3A, which was conserved at the time of posttransplantation relapse. All the ten patients with NPM1
mut relapse showed at least one detectable NPM1 mut value during follow-up (91% sensitivity), and seven out of ten showed two consecutive positive values, all with an increase in NPM1 mut transcript. Among the other three patients, two relapsed at 60 days after HSCT, so they had only one BM evaluation prior to relapse. Notably, seven patients never displayed any undetectable NPM1 mut value after transplant. The median time from first positive NPM1 mut determination to morphological relapse was 71 days (range 20-206), possibly a sufficient time to attempt a preemptive treatment, as also evidenced by previous studies 10 ( Figure 1a ). Seventeen patients in this study remained in long-term CR (LT-CR, median time of observation 633 days, 115-1332). At pre-transplant evaluation, nine of these patients were in CR and negative for NPM1 mut , five were in CR but NPM1 mut -positive, and three had active disease. Of interest, four of the total eight patients in pre-transplant molecular persistence and one of the eight patients with active disease achieved durable molecular remissions after having received conditioning regimens based on treosulfan, commonly considered a reduced-intensity agent. During their post-transplant follow-up 10 of the 17 non-relapsed patients (59%) showed persistent negativity for NPM1 mut during all the follow-up, whereas seven (41%) showed at least one sample with detectable NPM1 mut . Notably, in three out of these seven patients, the positive samples were only those immediately following HSCT, and NPM1 mut became rapidly undetectable in the following controls. Only two LT-CR patients showed two consecutive and increasing positive values; out of these two patients, one, who was transplanted in molecular persistence, showed increasing NPM1 mut at the beginning of his follow-up and then reached NPM1 mut clearance in a few months; the other patient died 3 months after HSCT of transplant-related mortality, thus impeding longer monitoring (Figure 1b) .
Taking together the results from our analysis, the single posttransplant positivity for NPM1 mut displays 91% sensitivity but only 59% specificity, whereas two consecutive and increasing detections showed 78% sensitivity and 89% specificity. Based on a receiver operating characteristic analysis (provided as Supplementary Information), performed with all the longitudinal observations of our series, any NPM1 mut positivity above the maximal sensitivity threshold was meaningful for relapse prediction, not supporting the use of cutoff values. However, it has also to be taken into account that ROC analysis might result suboptimal in this context, in which multiple measurements are performed over time in the same patient. 8 It should also be noted that setting an arbitrary threshold of 10 − 3 NPM1 mut copies/ABL copy for single determination would completely avoid false positives (100% specificity), still maintaining 81% sensitivity in relapse prediction. Of interest, these cutoff values are significantly lower than those identified in other studies performed in the transplant setting. [7] [8] [9] Comparing WT1 with NPM1 mut in the relapse cohort, nine out of the eleven patients (82%) had WT1 overexpression (defined according to the threshold identified by Cilloni et al. 11 ) during their follow-up, but most of them (seven out of nine) had just a single over-threshold value before relapse, with approximately 1 month of advance before the clinical event. Besides, in the longterm CR cohort, 11 out of 17 patients showed WT1 overexpression in at least one BM evaluation, suggesting limited leukemia specificity (35%). This result is unexpected, and in partial disagreement with previous reports, which reported a much better performance for this marker in the transplant setting. 12, 13 Considering quantitative hematopoietic chimerism, the analysis was performed in seven out of eleven relapsed patients, and only one patient showed a positive value (defined as a host chimerism above 1%) during post-transplant follow-up, 1 month before clinical recurrence. Furthermore, nine out of the sixteen evaluable CR patients showed at least one sample with high host-DNA percentage, with two patients showing persistent over-threshold chimerism, suggesting that, at least in this study, quantitative chimerism had lower sensitivity and specificity compared to other techniques (14% and 44%, respectively).
According to our results, isolate NPM1 mut positivity should not guide onto an aggressive approach, especially at early time-points of the post-transplantation follow-up. Nevertheless, a careful monitoring should be performed in these subjects, since 60% of those having NPM1 mut positivity at 30 days from HSCT will relapse. Besides, increasing values of NPM1 mut in BM samples, and more generally, positivity in consecutive samples, appeared highly Abbreviations: LT-CR = long-term complete remission; TRM = transplant-related mortality. Last follow-up referred to 30 November 2014, configuring a median follow-up of 255 days (range 53-1332). All conditioning regimens were performed with myeloablative purpose: in particular, Treosulfan was used at the full dose of 14 g/m 2 for 3 days.
Letter to the Editor suggestive of impending relapse, and thus should be managed with immediate pre-emptive treatment. It should however be emphasized that NPM1 mut is present in only a subset of AML patients, and in even fewer of those who receive allogeneic HSCT. Moreover, even though generally stable over the disease course, NPM1 mut can be lost during clonal evolution, 4 as occurred also in one of the cases included in our analysis. In this view, the evaluation of earlier events in leukemogenesis, such as mutations in DNMT3A or IDH1/2, appears worthy of future investigation: although these preleukemic mutations have been shown to persist after chemotherapy even in patients who will not relapse, 14, 15 in allogeneic HSCT the persistence of host hematopoiesis, especially if of clonal origin, would bring no benefit whatsoever, and might be more easily and safely targeted by 'soft' therapeutic measures such as tapering of immunosuppressants.
In conclusion, our findings support the usefulness of posttransplantation NPM1 mut monitoring, encouraging its use in all AML patients who carry the mutation at the time of diagnosis, possibly including it in a multi-gene MRD tracking strategy, to further improve early detection of impending relapse. 
